Merck's Keytruda in combination with chemotherapy outperformed chemotherapy alone in high-risk early-stage triple-negative breast cancer, marking the first immunotherapy regimen to do so.

Merck's Keytruda cancer drug showed positive results in the late-stage KEYNOTE-522 trial for high-risk early-stage triple-negative breast cancer (TNBC). The drug, in combination with chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to pre-operative chemotherapy alone, marking the first immunotherapy regimen to outperform chemotherapy in this patient population.

May 28, 2024
5 Articles

Further Reading